{"title":"Correction to Lancet Oncol 2024; 25: 1325–36","authors":"","doi":"10.1016/s1470-2045(24)00587-4","DOIUrl":null,"url":null,"abstract":"<em>Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.</em> Lancet Oncol <em>2024; <strong>25:</strong> 1325–36</em>—In this Article, the second sentence in the fifth paragraph of the Results section, should read “After initiating belzutifan treatment, one patient (2%) underwent two CNS-related surgeries (cyst drainage and haemangioblastoma removal for the same lesion), and one patient (2%) received local radiotherapy approximately 5 weeks after starting belzutifan treatment.” These corrections have been made to the online version as of Oct 28, 2024.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00587-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 2024; 25: 1325–36—In this Article, the second sentence in the fifth paragraph of the Results section, should read “After initiating belzutifan treatment, one patient (2%) underwent two CNS-related surgeries (cyst drainage and haemangioblastoma removal for the same lesion), and one patient (2%) received local radiotherapy approximately 5 weeks after starting belzutifan treatment.” These corrections have been made to the online version as of Oct 28, 2024.
Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.Lancet Oncol 2024; 25: 1325-36-在这篇文章中，结果部分第五段的第二句应为 "在开始接受贝珠单抗治疗后，一名患者（2%）接受了两次中枢神经系统相关手术（囊肿引流术和同一病灶的血管母细胞瘤切除术），一名患者（2%）在开始接受贝珠单抗治疗约5周后接受了局部放疗"。截至2024年10月28日的在线版本已做了上述更正。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
